EICHOR
● Recruiting
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
Condition: Atopic Dermatitis · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
About this study
This is a multi-center, randomized, double-blind, parallel, placebo-controlled phase 2 clinical study. A total of 403 adult participants with moderate to severe AD are planned to be enrolled to evaluate efficacy, safety, PK characteristics, immunogenicity, and changes in PD characteristics of IBI356.
This description comes directly from the study's public registry record.
Talk to the study team
wensheng zang · 0512-69566088 · wensheng.zang@innoventbio.com
shanl li · 0512-69566088 · shanl.li@innoventbio.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07330934